| Amy Dawnette Johnson, RN | |
|
222 Southway Ave Ste 2b, Lewiston, ID 83501-2703 | |
| (208) 799-5370 | |
| Not Available |
| Full Name | Amy Dawnette Johnson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 222 Southway Ave Ste 2b, Lewiston, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144557653 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 56939 (Idaho) | Primary |
| 163W00000X | Registered Nurse | N-23216 (Idaho) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elite Home Health | Clarkston, WA | Home health agency |
| St Joseph Regional Medical Center | Lewiston, ID | Hospital |
| Tri-state Memorial Hospital | Clarkston, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Joseph Hospital Llc | 8325325806 | 39 |
News Archive
In a multi-center, randomized, trial across Europe, electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.
The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
Perrigo Company today announced that together with its partner Cobrek Pharmaceuticals, Inc. final approval has been received from the U.S. Food and Drug Administration to manufacture and market Clindamycin Phosphate Foam 1%, a generic version of Evoclin® Foam 1% of Stiefel. As the ANDA was first to file with a Paragraph IV certification against Evoclin®, 180 days of generic exclusivity was granted by the U.S. Food and Drug Administration.
In the human brain, mechanical stress the amount of pressure applied to a particular area requires a delicate balance. Just the right force keeps neurons together and functioning as a system within the body, and proper nerve function is dependent on this tension.
› Verified 7 days ago
| Entity Name | St Joseph Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205368404 PECOS PAC ID: 8325325806 Enrollment ID: O20170606002496 |
News Archive
In a multi-center, randomized, trial across Europe, electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.
The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
Perrigo Company today announced that together with its partner Cobrek Pharmaceuticals, Inc. final approval has been received from the U.S. Food and Drug Administration to manufacture and market Clindamycin Phosphate Foam 1%, a generic version of Evoclin® Foam 1% of Stiefel. As the ANDA was first to file with a Paragraph IV certification against Evoclin®, 180 days of generic exclusivity was granted by the U.S. Food and Drug Administration.
In the human brain, mechanical stress the amount of pressure applied to a particular area requires a delicate balance. Just the right force keeps neurons together and functioning as a system within the body, and proper nerve function is dependent on this tension.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Dawnette Johnson, RN 341 Saint Johns Way, Lewiston, ID 83501-2436 Ph: (208) 750-7462 | Amy Dawnette Johnson, RN 222 Southway Ave Ste 2b, Lewiston, ID 83501-2703 Ph: (208) 799-5370 |
News Archive
In a multi-center, randomized, trial across Europe, electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.
The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
Perrigo Company today announced that together with its partner Cobrek Pharmaceuticals, Inc. final approval has been received from the U.S. Food and Drug Administration to manufacture and market Clindamycin Phosphate Foam 1%, a generic version of Evoclin® Foam 1% of Stiefel. As the ANDA was first to file with a Paragraph IV certification against Evoclin®, 180 days of generic exclusivity was granted by the U.S. Food and Drug Administration.
In the human brain, mechanical stress the amount of pressure applied to a particular area requires a delicate balance. Just the right force keeps neurons together and functioning as a system within the body, and proper nerve function is dependent on this tension.
› Verified 7 days ago
Mrs. Nicole M Engledow, ARPN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 500 8th Ave, Lewiston, ID 83501 Phone: 208-792-2685 Fax: 208-792-2882 | |
Susan P Stutzman, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 215 10th St, Lewiston, ID 83501 Phone: 208-799-3100 Fax: 208-799-0349 | |
Anita Ringering, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 336 Warner Dr, Ste 4, Lewiston, ID 83501 Phone: 208-413-3835 | |
Robert Scott Mahal, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2315 8th St, Lewiston, ID 83501 Phone: 208-746-1383 Fax: 208-746-6348 | |
Spencer Godfrey, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1203 Idaho St, Lewiston, ID 83501 Phone: 208-848-8300 | |
Tracy Streibick Flynn, FNP, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1203 Idaho St, Lewiston, ID 83501 Phone: 208-848-8300 | |
Tayler Lyndsey Holman, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3428 5th St, Lewiston, ID 83501 Phone: 509-552-6674 |